Josh Resnick, MD

Josh is a managing director at RA Capital Management. Josh’s primary responsibility at RA Capital Management is to lead early-stage private investments in and oversee the creation of new companies developing drugs, medical devices, diagnostics, and research tools. He serves on the boards of multiple oncology companies including Vor Biopharma, EnaraBio, and T-knife. He has more than 15 years of experience in investing, company formation, and company leadership across all stages of drug development, from discovery through commercialization. Josh was previously co-lead of SV Health Investors’ U.S. Biotech practice where he was responsible for SV’s U.S. venture creation activities, including its incubator, Brahma Discovery. Before SV, Josh was president and managing partner at MRL Ventures Fund, the early-stage therapeutics-focused corporate venture fund within Merck & Co. Prior to MRL Ventures, Josh was a venture partner with Atlas Venture and a partner at Prism Venture Partners, focusing on company formation and seed and Series A investing. Josh is currently a faculty member at Harvard Medical School and continues to practice medicine as an attending physician in the Department of Emergency Medicine at Massachusetts General Hospital. He holds a B.A. in chemistry from Williams College, an M.D. from the University of Pennsylvania School of Medicine, and an MBA from the Wharton School of Business.